1. Home
  2. KBDC vs CMPX Comparison

KBDC vs CMPX Comparison

Compare KBDC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

HOLD

Current Price

$14.55

Market Cap

980.7M

Sector

N/A

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBDC
CMPX
Founded
2021
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.7M
927.5M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
KBDC
CMPX
Price
$14.55
$2.06
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$15.50
$14.57
AVG Volume (30 Days)
230.7K
12.1M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
13.16%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
N/A
N/A
Revenue This Year
$193.84
N/A
Revenue Next Year
$9.00
$934.41
P/E Ratio
$34.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.06
$1.61
52 Week High
$16.28
$6.88

Technical Indicators

Market Signals
Indicator
KBDC
CMPX
Relative Strength Index (RSI) 48.26 34.36
Support Level $14.02 $1.61
Resistance Level $15.02 $3.54
Average True Range (ATR) 0.38 0.14
MACD -0.07 0.13
Stochastic Oscillator 7.41 78.75

Price Performance

Historical Comparison
KBDC
CMPX

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: